Stres hiperglikemija u akutnom infarktu miokarda

Bernard C. Lessons from experimental physiology applied to the medicine. Paris: Balliere; 1855. p. 296−313. (French)

Johan Groeneveld AB, Beishuizen A, Visser FC. Insulin: a wonder drug in the critically ill? Crit Care 2002; 6(2): 102−5.

Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. AACN Clin Issues 2006; 17(1): 50−5.

van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345(19): 1359−67.

McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyper-glycemia. Crit Care Clin 2001; 17(1): 107−24.

Nasraway SA Jr. Hyperglycemia during critical illness. JPEN J Parenter Enteral Nutr 2006; 30(3): 254−8.

Koraćević G, Petrović S, Tomašević M, Apostolović S, Damjanović M. Stress hyperglycemia in acute myocardial infarction. Facta Universitatis (Medicine and Biology) 2006; 13(3): 152−7.

Stubbs PJ, Laycock J, Alaghband-Zadeh J, Carter G, Noble MI. Circulating stress hormone and insulin concentrations in acute coronary syndromes: Identification of insulin resis-tance on admission. Clin Sci (Lond) 1999; 96(6): 589−95.

Van Cromphaut SJ. Hyperglycaemia as part of the stress re-sponse: the underlying mechanisms. Best Pract Res Clin Anaesthesiol 2009; 23(4): 375−86.

Langouche L, van den Berghe G. The dynamic neuroendocrine response to critical illness. Endocrinol Metab Clin North Am 2006; 35(4): 777−91.

van den Berghe G. Neuroendocrine pathobiology of chronic critical illness. Crit Care Clin 2002; 18(3): 509−28.

Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5(5): 551−9.

Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004; 30(5): 748−56.

Koracevic GP. The consensus is clearly needed for the defini-tion of stress hyperglycaemia in acute myocardial infarction. Eur Heart J 2007; 28(16): 2042.

Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Xu K, et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percu-taneous coronary intervention: The HORIZONS-AMI trial. Int J Cardiol 2013; 167(6): 2572−9.

Timmer JR, Hoekstra M, Nijsten MW, Horst IC, Ottervanger JP, Slingerland RJ, et al. Prognostic value of admission glycosy-lated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011; 124(6): 704−11.

Mladenović V, Zdravković V, Jović M, Vucić R, Irić-Cupić V, Rosić M. Influence of admission plasma glucose level on short- and long-term prognosis in patients with ST-segment elevation myocardial infarction. Vojnosanit Pregl 2010; 67(4): 291−5.

Teraguchi I, Imanishi T, Ozaki Y, Tanimoto T, Kitabata H, Ino Y, et al. Impact of stress hyperglycemia on myocardial salvage following successfully recanalized primary acute myocardial infarction. Circ J 2012; 76(11): 2690−6.

Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010; 55(22): 2470−9.

Stojković A, Koracević G, Perisić Z, Krstić N, Pavlović M, Todorović L, et al. The influence of stress hyperglycemia on the prog-nosis of patients with acute myocardial infarction and tem-porary electrical cardiac pacing. Srp Arh Celok Lek 2010; 138(7−8): 430−5. (Serbian)

Pres D, Gasior M, Strojek K, Gierlotka M, Hawranek M, Lekston A, et al. Blood glucose level on admission determines in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock treated with percutaneous coronary intervention. Kardiol Pol 2010; 68(7): 743−51.

Deckers JW, van Domburg RT, Akkerhuis M, Nauta ST. Relation of Admission Glucose Levels, Short- and Long-Term (20-Year) Mortality After Acute Myocardial Infarction. Am J Cardiol 2013; 112(9): 1306−10.

de Mulder M, Cornel J, Ploeg T, Boersma E, Umans VA. Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy. Am Heart J 2010; 160(3): 412−9.

Ladeira RT, Baracioli LM, Faulin TE, Abdalla DS, Seydell TM, Maranhão RC, et al. Unrecognized diabetes and myocardial necrosis: predictors of hyperglycemia in myocardial infarc-tion. Arq Bras Cardiol 2013; 100(5): 404−11.

Naber CK, Mehta RH, Jünger C, Zeymer U, Wienbergen H, Sabin GV, et al. Impact of admission blood glucose on outcomes of nondiabetic patients with acute ST-elevation myocardial infarction (from the German Acute Coronary Syndromes [ACOS] Registry). Am J Cardiol 2009; 103(5): 583−7.

Chen J, Tseng C, Tsai S, Chiu W. Initial serum glucose level and white blood cell predict ventricular arrhythmia after first acute myocardial infarction. Am J Emerg Med 2010; 28(4): 418−23.

Sanjuan R, Blasco ML, Martinez-Maicas H, Carbonell N, Miñana G, Nuñez J, et al. Acute myocardial infarction: high risk ven-tricular tachyarrhythmias and admission glucose level in pa-tients with and without diabetes mellitus. Curr Diabetes Rev 2011; 7(2): 126−34.

Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994; 343(8890): 155−8.

Oliver MF. Metabolic causes and prevention of ventricular fi-brillation during acute coronary syndromes. Am J Med 2002; 112(4): 305−11.

Koracevic GP, Petrovic S, Damjanovic MR, Stanojlovic T. Associa-tion of stress hyperglycemia and atrial fibrillation in myocar-dial infarction. Wien Klin Wochenschr 2008; 120(13−14): 409−13.

Dziewierz A, Giszterowicz D, Siudak Z, Rakowski T, Dubiel JS, Dudek D. Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction. Clin Res Cardiol 2010; 99(11): 715−21.

Sanjuán R, Núñez J, Blasco ML, Miñana G, Martínez-Maicas H, Carbonell N, et al. Prognostic implications of stress hypergly-cemia in acute ST elevation myocardial infarction. Prospec-tive observational study. Rev Esp Cardiol 2011; 64(3): 201−7.

Nakamura T, Ako J, Kadowaki T, Funayama H, Sugawara Y, Kubo N, et al. Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction. J Cardiol 2009; 53(2): 272−7.

Timmer JR, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Gosselink AT, et al. Hyperglycemia is an important pre-dictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005; 45(7): 999−1002.

Djordjevic-Radojkovic D, Koracevic G, Stanojevic D, Damjanovic M, Apostolovic S, Pavlovic M. Stress hyperglycemia in acute ST-segment elevation myocardial infarction is a marker of left ventricular remodeling. Acute Card Care 2013; 15(2): 38−43.

Stanojevic D, Apostolovic SR, Koracevic GP, Jankovic-Tomasevic R, Pavlovic M, Djordjevic-Radojkovic DD, et al. Stress hyperglycemia as an indicator of in-hospital and 6 month prognosis in acute myocardial infarction and its correlation with endo-thelial dysfunction. Circulation 2012; 125(19): E861.

Marik PE, Bellomo R. Stress hyperglycemia: an essential sur-vival response. Crit Care Med 2013; 41(6): e93−4.

Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008; 117(12): 1610−9.

Bhadriraju S, Ray KK, de Franco AC, Barber K, Bhadriraju P, Murphy SA, et al. Association between blood glucose and long-term mortality in patients with acute coronary syn-dromes in the OPUS-TIMI 16 trial. Am J Cardiol 2003; 97(11): 1573−7.

Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005; 46(1): 178−80.

Koracevic GP, Krstic NH, Damjanovic MR, Velickovic-Radovanovic RM, Apostolovic SR, Pavlovic S, et al. Two different cut-off values for stress hyperglycemia in myocardial infarction. HealthMED 2012; 6(7): 2507−12.

Koracevic GP. Stress hyperglycemia -better prognosticator with different cut-offs. Am J Med 2013; 126(5): e9.

Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hypergly-caemia and increased risk of death after myocardial infarc-tion in patients with and without diabetes: A systematic overview. Lancet 2000; 355(9206): 773−8.

O'Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R. In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 1991; 14(8): 758−60.

Sewdarsen M, Vythilingum S, Jialal I, Becker PJ. Prognostic im-portance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. Q J Med 1989; 71(265): 461−6.

Choi SW, Benzie IF, Ma SW, Strain JJ, Hannigan BM. Acute hyperglycemia and oxidative stress: direct cause and effect. Free Radic Biol Med 2008; 44(7): 1217−31.

Ling P, Smith RJ, Bistrian BR. Hyperglycemia enhances the cy-tokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med 2005; 33(5): 1084−9.

Marfella R, Siniscalchi M, Esposito K, Sellitto A, de Fanis U, Ro-mano C, et al. Effects of stress hyperglycemia on acute myo-cardial infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003; 26(11): 3129−35.

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106(16): 2067−72.

Iwasaki Y, Kambayashi M, Asai M, Yoshida M, Nigawara T, Ha-shimoto K. High glucose alone, as well as in combination with proinflammatory cytokines, stimulates nuclear factor kappa-B-mediated transcription in hepatocytes in vitro. J Diabetes Complications 2007; 21(1): 56−62.

Perner A, Nielsen SE, Rask-Madsen J. High glucose impairs superoxide production from isolated blood neutrophils. In-tensive Care Med 2003; 29(4): 642−5.

Nielson CP, Hindson DA. Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentra-tions in vitro. Diabetes 1989; 38(8): 1031−5.

Dhingra S, Sharma AK, Arora RC, Slezak J, Singal PK. IL-10 attenuates TNF-alpha-induced NF kappaB pathway activa-tion and cardiomyocyte apoptosis. Cardiovasc Res 2009; 82(1): 59−66.

Nizamutdinova IT, Guleria RS, Singh AB, Kendall JA, Baker KM, Pan J. Retinoic acid protects cardiomyocytes from high glucose-induced apoptosis through inhibition of NF-κB sig-naling pathway. J Cell Physiol 2013; 228(2): 380−92.

Cai L, Li W, Wang G, Guo L, Jiang Y, Kang JY. Hyperglyce-mia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002; 51(6): 1938−48.

Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A. Inter-mittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001; 281: 924−930.

Stegenga ME, Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy hu-mans. Diabetes 2006; 55(6): 1807−12.

Tang WH, Cheng WT, Kravtsov GM, Tong XY, Hou XY, Chung SK, et al. Cardiac contractile dysfunction during acute hyper-glycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 2010; 299(3): C643−53.

Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, Lie-shout MH, Levi M, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55(2): 480−6.

Kersten JR, Schmeling TJ, Orth KG, Pagel PS, Warltier DC. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 1998; 275(2 Pt 2): H721−5.

Lazaros G, Tsiachris D, Vlachopoulos C, Chrysohoou C, Milkas A, Papageorgiou N, et al.. Distinct association of admission hyperglycemia with one-year adverse outcome in diabetic and non-diabetic patients with acute ST-elevation myocardial infarction. Hellenic J Cardiol 2013; 54(2): 119−25.

Tamita K, Katayama M, Takagi T, Yamamuro A, Kaji S, Yoshi-kawa J, et al. Newly diagnosed glucose intolerance and prog-nosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations. Heart 2012; 98(11): 848−54.

Pinheiro CP, Oliveira MD, Faro GB, Silva EC, Rocha EA, Barreto-Filho JA, et al. Prognostic value of stress hyperglycemia for in-hospital outcome in acute coronary artery disease. Arq Bras Cardiol 2013; 100(2): 127−34.

Marfella R, Verrazzo G, Acampora R, la Marca C, Giunta R, Lu-carelli C, et al. Glutathione reverses systemic hemodynamic changes by acute hyperglycaemia in healthy subjects. Am J Physiol 1995; 268 (6 Pt 1): E1167−73.

Takada JY, Ramos RB, Roza LC, Avakian SD, Ramires JA, Mansur AP. In-hospital death in acute coronary syndrome was related to admission glucose in men but not in women. Cardiovasc Diabetol 2012; 11: 47.

Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first an-terior wall acute myocardial infarction. Am Heart J 2003;146(4): 674−8.

Ishihara M. Acute hyperglycemia in patients with acute myo-cardial infarction. Circ J 2012; 76(3): 563−71.

Singla A, Orshaw P, Boura J, Harjai KJ. Glycosylated hemog-lobin and outcomes in diabetic patients with acute myo-cardial infarction after successful revascularization with stent placement: findings from the guthrie health off-label stent (GHOST) investigators. J Interv Cardiol 2012; 25(3): 262−9.

Jensen CJ, Eberle HC, Nassenstein K, Schlosser T, Farazandeh M, Naber CK, et al. Impact of hyperglycemia at admission in pa-tients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI. Clin Res Cardiol 2011; 100(8): 649−59.

Ege M, Güray U, Güray Y, Yılmaz MB, Demirkan B, Saşmaz A, et al. Relationship between TIMI frame count and ad-mission glucose values in acute ST elevation myocardial in-farction patients who underwent successful primary percu-taneous intervention. Anadolu Kardiyol Derg 2011; 11(3): 213−7.

Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41(1): 1−7.

Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giug-liano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000; 43(5): 571−5.

Hoebers LP, Damman P, Claessen BE, Vis MM, Baan J, Straalen JP, et al. Predictive value of plasma glucose level on admis-sion for short and long term mortality in patients with ST-elevation myocardial infarction treated with primary percu-taneous coronary intervention. Am J Cardiol 2012; 109(1): 53−9.

Ceriello A. Acute hyperglycaemia and oxidative stress genera-tion. Diabet Med 1997; 14(Suppl 3): S45−9.

Marfella R, Sasso FC, Siniscalchi M, Paolisso P, Rizzo MR, Ferraro F, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab 2012; 97(8): 2862−71.

Kuliczkowski W, Gąsior M, Pres D, Kaczmarski J, Greif M, Łaszewska A, et al.. Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol 2012; 110(3): 331−6.

Vivas D, García-Rubira JC, Bernardo E, Angiolillo DJ, Martín P, Calle-Pascual A, et al. Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coro-nary syndrome. A subanalysis of the CHIPS Study. J Thromb Thrombolysis 2013; 35(2): 165−74.

Li D, Hua Q, Guo J, Li H, Chen H, Zhao S. Admission glu-cose level and in-hospital outcomes in diabetic and non-diabetic patients with ST-elevation acute myocardial infarc-tion. Intern Med 2011; 50(21): 2471−5.

Liao WI, Sheu WH, Chang WC, Hsu CW, Chen YL, Tsai SH. An Elevated Gap between Admission and A1C-Derived Average Glucose Levels Is Associated with Adverse Outcomes in Diabetic Patients with Pyogenic Liver Abscess. PLoS One 2013; 8(5): e64476.

Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135(1): 41−60.

Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D, Brogan GX, et al. Prevalence and clinical outcomes of un-diagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J 2013; 165(6): 918−25.

ShaoNan L, GuangLian L, XiaoMing L, Zhen L, KaiWei F, Jian L, et al. The relationship between stress-induced hypergly-cemia and myocardial ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percu-taneous coronary intervention. Chinese J Pract Intern Med 2009; 29(12): 1126−29.

Eitel I, Hintze S, de Waha S, Fuernau G, Lurz P, Desch S, et al. Prognostic impact of hyperglycemia in nondiabetic and di-abetic patients with ST-elevation myocardial infarction: in-sights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 2012; 5(6): 708−18.

Zhang J, Zhou Y, Cao S, Yang Q, Yang S, Nie B. Impact of stress hyperglycemia on in-hospital stent thrombosis and prognosis in nondiabetic patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis 2013; 24(5): 352−6.

Ergelen M, Uyarel H, Cicek G, Isik T, Osmonov D, Gunaydin ZY, et al. Which is worst in patients undergoing primary angiop-lasty for acute myocardial infarction? Hyperglycaemia? Di-abetes mellitus? Or both. Acta Cardiol 2010; 65(4): 415−23.

Mather AN, Crean A, Abidin N, Worthy G, Ball SG, Plein S, et al. Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardi-ovascular magnetic resonance. J Cardiovasc Magn Reson 2010; 12(1): 61.

Sanjuán R, Núñez J, Blasco LM, Miñana G, Martínez-Maicas H, Carbonell N, et al. Prognostic implications of stress hypergly-cemia in acute ST elevation myocardial infarction. Prospec-tive observational study. Rev Esp Cardiol 2011; 64(3): 201−7.

Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Haemoglo-bin A(1c) , acute hyperglycaemia and short-term prognosis in patients without diabetes following acute ST-segment ele-vation myocardial infarction. Diabet Med 2012; 29(12): 1493−500.

Stolker JM, McCullough PA, Rao S, Inzucchi SE, Spertus JA, Maddox TM, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients under-going coronary angiography. J Am Coll Cardiol 2010; 55(14): 1433−40.

Alpert MA, Carlino C. Pre-procedural blood glucose levels: a new risk marker for contrast-induced acute kidney injury in patients without diabetes with acute myocardial infarction. J Am Coll Cardiol 2010; 55(14): 14413.

GuoHong Y, Wang Wei W. Predictive value of admission se-rum glucose level on hospitalized mortality in acute myocar-dial infarction after percutaneous coronary intervention. Biomed Engineering Clin Med 2009; 13(1): 31−3.

Mrdovic I, Savic L, Krljanac G, Asanin M, Perunicic J, Lasica R, et al. Predicting 30-day major adverse cardiovascular events af-ter primary percutaneous coronary intervention. The RISK-PCI score. Int J Cardiol 2013; 162(3): 220−7.

Pei-Chi C, Su-Kiat C, Huei-Fong H, Chung-Yen H, Chiu-Mei L, Shih-Ming L, et al. Admission hyperglycemia predicts poorer short- and long-term outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction. J Diabetes Invest 2013; doi: 10.1111/jdi.12113.

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20): 2569−619.

Dhatariya K. Should inpatient hyperglycaemia be treated. Br Med J 2013; 346: f134.

Chandrasekara H, Brough C, Goenka N, Somauroo J, Hardy K. Management of hyperglycaemia in people with acute coro-nary syndromes (NICE Clinical Guideline 130): uncertainty persists (pages 9-11). Pract Diabet 2012; 29(1): 7−37.

Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354(5): 449−61.

Van den Berghe G, Wilmer A, Milants I, Wouters PJ, Bouckaert B, Bruyninckx F, et al. Intensive insulin therapy in mixed medi-cal/surgical intensive care units: benefit versus harm. Di-abetes 2006; 55(11): 3151−9.

Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den Heuvel I, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised con-trolled study. Lancet 2009; 373(9663): 547−56.

Mesotten D, van den Berghe G. Glycemic targets and approaches to management of the patient with critical illness. Curr Diab Rep 2012; 12(1): 101−7.

Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guide-line and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60(7): 645−81.

Hamm CW, Bass JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(23): 2999−3054.

Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarc-tion (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26(7): 650−61.

Cheung NW, Wong VW, McLean M. The Hyperglycemia: In-tensive Insulin Infusion in Infarction (HI-5) study: a rando-mized controlled trial of insulin infusion therapy for myo-cardial infarction. Diabetes Care 2006; 29(4): 765−70.

Chatterjee S, Sharma A, Lichstein E, Mukherjee D. Intensive Glucose Control in Diabetics with an Acute Myocardial In-farction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis. Curr Vasc Pharmacol 2013; 11(1): 100−4.

Centre for Clinical Practice at NICE (UK). Hyperglycaemia in Acute Coronary Syndromes: Management of Hyperglycae-mia in People with Acute Coronary Syndromes. London: National Institute for Health and Clinical Excellence (UK); 2011.

Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic pa-tients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26(1): 57−65.

Diaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007; 298(20): 2399−405.

Vivas D, Bernardo E, Palacios-Rubio J, Fernández-Ortiz A. How to manage hyperglycemia in an acute coronary syndrome pa-tient. Curr Treat Options Cardiovasc Med 2013; 15(1): 93−103.

Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, et al. Effect of glucoseinsulin- potassium infusion on mortality in pa-tients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293(4): 437−46.

Timmer JR, Svilaas T, Ottervanger JP, Henriques JP, Dambrink JH, van den Broek SA, et al. Glucoseinsulin- potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol 2006; 47(8): 1730−1.

Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'agostino RB, et al. Out-of-hospital administration of intra-venous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 2012; 307(18): 1925-−33.

Svensson AM, Mcguire DK, Abrahamsson P, Dellborg M. Associa-tion between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005; 26: 1255−61.

Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53(8): 1552−61.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. . Management of hyperglycaemia in type 2 diabetes: a patient- centered approach. Position statement of the American Diabetes Association (ADA) and the Euro-pean Association for the Study of Diabetes (EASD). Diabe-tologia 2012; 55(6): 1577−96.

Kishore P, Kim SH, Crandall JP. Glycemic control and cardi-ovascular disease: what's a doctor to do. Curr Diab Rep 2012; 12(3): 255−64.

Nusca A, Patti G, Marino F, Mangiacapra F, D'ambrosio A, Di Sciascio G. Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. Catheter Cardiovasc Interv 2012; 80(3): 377−84.

Korsiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, et al. Relationship between spontaneous and ia-trogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009; 301(15): 1556−64.

Flower O, Finfer S. Glucose control in critically ill patients. In-tern Med J 2012; 42(1): 4−6.

Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and im-proves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53(6): 501−10.

Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109(8): 962−5.

Vergès B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, et al. Consensus statement on the care of the hyperglycae-mic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab 2012; 38(2): 113−27.

American Diabetes Association. Standards of Medical Care in Diabetes - 2010. Diabetes Care 2010; 33(Suppl 1): S11−61.

McGregor AK, Leech N, Purcell IF, Edwards R. Effect of prima-ry percutaneous coronary intervention on stress hypergly-caemia in myocardial infarction. Diabet Med 2012; 29(10): 1317−20.

Scottish Intercollegiate Guidelines Network. Acute coronary syndromes (SIGN 116). 2011. [cited 2012 Feb 11]. Available from: www.sign.ac.uk/pdf/sign116.pdf

Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Use of intensive insulin therapyfor the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 154(4): 260−7.

O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Man-agement of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(4): 362−425.

Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Deutschman C, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012; 40(12): 3251−76.

Ye Y, Xie H, Zhao X, Zhang S. The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diag-nostic test accuracy. Cardiovasc Diabetol 2012; 11: 155.

Rydén L, Standl E, Bartnik M, van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and car-diovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European So-ciety of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1): 88−136.

Chakrabarti AK, Singh P, Gopalakrishnan L, Kumar V, Doherty EM, Abueg C, et al. Admission hyperglycemia and acute myocardial infarction: outcomes and potential therapies for diabetics and nondiabetics. Cardiol Res Pract 2012; 2012: 704314.